The Cannabis Finance Problem Just Changed — What Rescheduling Means for 280E, Banking, and Capital
The Cannabis Finance Problem Just Changed — What Rescheduling Means for 280E, Banking, and Capital
In April 2026 the federal ground under the cannabis industry moved for the first time in fifty years. Most operators have not yet repriced their financial strategy around what changed — or, just as important, around what did not.
2026
2026
For two decades, cannabis finance was defined by three structural disadvantages that no amount of operating skill could fully overcome: a punishing tax code, a banking system that would not take the industry's money, and a capital market that priced regulatory risk into every dollar. In April 2026, one of those three started to move. The operators who understand exactly how much moved — and how much did not — will make materially better financial decisions over the next eighteen months than those who read a headline and assumed the problem was solved.
I have sat in the CFO seat for cannabis operators on both sides of this divide: leading financial operations for a publicly listed cannabis company through 41% and 60% revenue-growth years and the full weight of SEC reporting, and securing $20M/$75.5M in debt financing from a publicly listed cannabis REIT to fund multi-state cultivation and dispensary expansion. What I learned in those roles is that cannabis is not a normal business wearing a different label. The tax, banking, and capital constraints are not friction at the edges — they sit at the center of every financial decision an operator makes. This article explains where those constraints stand today, after the most consequential federal action the industry has seen.
What Actually Changed in April 2026 — and What Did Not
On April 23, 2026, the Department of Justice and the Drug Enforcement Administration issued a final order that, effective April 28, 2026, moved two narrow categories of marijuana from Schedule I to Schedule III of the Controlled Substances Act: marijuana contained in FDA-approved drug products, and marijuana produced and dispensed under a qualifying state medical marijuana license. At the same time, the DEA announced an expedited administrative hearing, beginning June 29, 2026, to consider whether marijuana more broadly — including adult-use — should also be reclassified.
That is a real change, and a narrow one. The distinction that now governs cannabis finance is no longer simply “legal under state law” versus “illegal under federal law.” It is a sharper line: state-licensed medical activity has moved to Schedule III, while adult-use (recreational) cannabis remains in Schedule I. For an industry where most revenue in mature markets comes from adult-use sales, that distinction is the whole game.
Two cautions belong next to that timeline. First, the April order is widely expected to draw legal challenges, so the durability of even the narrow change is not guaranteed. Second, the broader question — the one that matters most to adult-use operators — is exactly what the June 29 hearing will take up, and a hearing is not an outcome. The honest planning posture is to treat the medical reclassification as in effect today and the broader reclassification as a live possibility, not a certainty, with timing that could stretch well beyond 2026.
280E: The Tax Rule That Defined Cannabis Finance
If you understand only one thing about cannabis finance, make it Section 280E of the Internal Revenue Code. It is the single provision that has done the most to shape how cannabis businesses are capitalized, valued, and run.
Section 280E denies businesses “trafficking” in Schedule I or II controlled substances the ordinary deductions and credits that every other business takes for granted — rent, payroll, marketing, professional fees, and most operating costs. The one thing it does not disallow is cost of goods sold. The practical result is that a cannabis business is taxed on a base that looks far larger than its real economic profit, because the costs of actually running the business are largely non-deductible for federal purposes.
What rescheduling does to 280E — and the trap in the details
Here is the mechanically important point: Section 280E applies only to Schedule I and Schedule II substances. Move an activity to Schedule III, and 280E no longer reaches it. So for the categories rescheduled in April — FDA-approved products and state-licensed medical cannabis — the 280E burden is, in principle, lifted going forward.
That is genuinely good news for medical operators, and it is also where careful operators slow down rather than speed up. Three details deserve attention before anyone changes a tax position:
- Adult-use is unaffected. Recreational cannabis remains Schedule I, so 280E continues to apply to adult-use activity in full.
- Dual operators sit in a gray zone. For a business that sells both medical and adult-use product, how 280E applies across the combined operation is unsettled. Treasury and the IRS announced in April 2026 that they intend to issue guidance, and signaled that 280E should apply only to the activities that involve trafficking in Schedule I or II substances — for example, by apportioning expenses between medical and adult-use activity. The mechanics, transitional rules, and timing of that guidance remain to be seen, and allocation decisions should not be made informally.
- Effective dates and method changes matter. When relief begins, how it interacts with prior-year positions, and how to handle inventory and accounting-method questions are technical matters with real dollar consequences and real audit exposure.
The right move after April 2026 is not to assume your tax bill fell. It is to model both worlds — relief and no relief — with qualified tax counsel, and to make sure your books can actually support whatever position you take if the IRS asks. Rescheduling rewards operators whose accounting was already clean. It punishes those who improvise.
Banking: Still Broken, and Rescheduling Did Not Fix It
It would be reasonable to assume that a federal reclassification loosens the banking logjam. For most operators, it does not — and understanding why is essential to running the business safely.
The reason banks avoid the industry is not the schedule number itself but the exposure that flows from federal illegality: money-laundering risk, the threat of regulatory action, and uncertainty about deposit insurance when an institution knowingly handles proceeds from federally illegal activity. Because most cannabis revenue — adult-use — remains in Schedule I, that exposure is still very much alive. Reclassifying medical activity does not change the calculus for the bulk of the industry's cash.
The legislative fix that would actually create a safe harbor is the SAFER Banking Act. As of June 2026 it has been reintroduced with bipartisan Senate sponsorship, it has cleared the Senate Banking Committee in a prior session, and it has passed the House multiple times over the years — but it has not received a full Senate floor vote, and it remains stalled. The pattern the industry knows well is momentum followed by delay. Until explicit safe-harbor legislation passes, the fundamental banking problem persists, and federal payment-services guidance has not been refreshed to match the new landscape.
In the meantime, operators continue to run on a patchwork: a limited set of cannabis-banking programs at smaller institutions and credit unions, compliance-heavy account relationships, and a steady migration toward bank-to-bank and ACH payment rails to reduce reliance on cash at the register. None of that removes the core CFO obligations the industry has always carried: disciplined cash handling, tight internal controls, and reconciliation rigor that can withstand both a regulator and a buyer.
Capital Access: Why Cannabis Money Is Scarce and Expensive
The third structural disadvantage is the cost and availability of capital, and it is the one I spent the most time solving directly as a cannabis CFO. Plant-touching operators are generally locked out of the financing sources most businesses lean on: SBA programs are unavailable, and traditional bank term loans are largely off the table. That leaves a narrower, more expensive menu, and a lender pool that prices regulatory risk into everything.
Two structures do disproportionate work here. Private and specialty debt funds stepped into the gap left by banks, lending against cash flow and assets at rates that reflect the risk and the scarcity. Sale-leaseback and REIT financing converts owned real estate — cultivation facilities, dispensaries — into upfront capital by selling the property and leasing it back, which is how a great deal of expansion in this industry has been funded. The $20M/$75.5M debt financing I led was sourced from a publicly listed cannabis REIT precisely because that channel was open when conventional debt was not. Each structure carries real trade-offs: rate and covenant load on the debt side, long-term lease obligations on the sale-leaseback side, and permanent dilution on the equity side. Choosing among them is a CFO-level decision, not a financing formality.
Does rescheduling change the capital picture? Over time, possibly — a cleaner federal status and the removal of 280E for some activity improve after-tax cash flow and could gradually widen the lender pool and support better terms and, eventually, broader exchange access. But that is a multi-year arc contingent on what happens after June 29 and on whether the banking framework catches up. For financing decisions an operator is making this year, the prudent assumption is that cannabis capital remains scarcer and costlier than it is for comparable businesses elsewhere.
Medical vs. Adult-Use: The Distinction That Now Drives the Numbers
Because the April order split the industry by license type, the single most useful thing an operator can do is understand which side of the line each part of the business sits on, and plan the finances accordingly.
Moved to Schedule III
280E no longer reaches qualifying activity going forward, which can materially improve after-tax cash flow — with the timing and mechanics requiring tax counsel.
Federal status is cleaner, though banking exposure is not fully resolved and the order may be challenged.
Remains Schedule I
280E continues to apply in full. Tax, banking, and capital constraints are effectively unchanged for now.
The June 29 hearing will consider broader reclassification, but the outcome and timing are uncertain.
For pure-play medical operators, the planning question is how and when to capture relief, correctly. For adult-use operators, it is how to stay disciplined through a period when relief is plausible but not present. For dual operators — the most common structure in mature markets — it is how to allocate, document, and defend positions across a business that now straddles two federal schedules. None of those questions has a generic answer, which is exactly why this is a moment for specialized financial leadership rather than a template.
What Operators Should Do Now
Regulatory inflection points reward preparation and punish improvisation. These are the moves I would prioritize as a CFO in the back half of 2026 — each to be executed with the appropriate licensed advisor, not in isolation.
Re-run your tax position with qualified counsel
Model your federal tax under both relief and no-relief scenarios for each license type. Decide nothing about 280E informally, and document the basis for whatever position you take.
Make your books defensible before you need them to be
Clean inventory and cost-of-goods accounting, tight cost allocation, and reconciliation discipline are what let you actually claim relief, survive an audit, and pass a buyer's diligence. Rescheduling rewards operators whose accounting was already in order.
Pressure-test cash and banking continuity
Assume the banking fix does not arrive on your timeline. Confirm account stability, reduce cash-handling risk, and build the internal controls a regulator or institutional partner would expect.
Plan capital around multiple regulatory outcomes
Before committing to debt, a sale-leaseback, or an equity round, model how each structure performs if broader reclassification happens, if it stalls, and if the April order is challenged. The right instrument changes with the scenario.
Scenario-plan the June 29 hearing
Treat the hearing as a branch point, not a verdict. Build a simple decision framework now for what you do under each plausible outcome so you can move quickly when there is news, rather than reacting late.
The cannabis finance problem did not disappear in April 2026. It fractured into a more complicated, more opportunity-laden problem — one where the gap between a prepared operator and an improvising one is wider than it has ever been. The operators who treat this as a financial-strategy moment, not just a legal headline, will be the ones positioned to benefit if and when the broader change arrives.
Glossary
Frequently Asked Questions
Cannabis finance is a specialist's problem. I have done it from the CFO seat.
I have led financial operations for a publicly listed cannabis company through SEC reporting and rapid growth, and sourced REIT debt financing for multi-state cultivation and dispensary expansion. If you are weighing what April's changes mean for your tax position, your banking, or your next capital raise, let's talk through your specific situation.
Talk About Your Situation →Notes & Sources
Disclosure & Important Disclaimers
General information only. This article is provided for general educational and informational purposes for cannabis business owners, operators, and the finance and accounting professionals who serve them. It is not directed to investors and is not investment research, a recommendation, or a solicitation with respect to any security. It is not, and must not be relied upon as, legal, tax, accounting, securities, investment, or regulatory-compliance advice, and it is not a substitute for advice from a licensed professional engaged on your specific facts. Reading it does not create any attorney-client, accountant-client, or advisory relationship.
Federal legal status. Cannabis remains illegal under federal law in most respects, including adult-use cannabis, which remained a Schedule I controlled substance as of the date of publication. Nothing in this article is intended to encourage, promote, facilitate, or assist any activity that violates federal law, and nothing here should be read as an opinion on the legality of any business or transaction.
Rapidly changing and uncertain. The regulatory, tax, and legislative matters discussed here are evolving quickly. Statements about rescheduling, Section 280E, banking legislation, and future proceedings reflect information available as of June 2026 and are subject to change, agency interpretation, transitional guidance, and legal challenge. Forward-looking statements about possible outcomes are inherently uncertain. Figures and examples are illustrative and simplified and do not reflect any specific business.
Get your own advisors. Before taking or changing any tax, accounting, banking, financing, or compliance position, consult your own qualified attorney, tax advisor, and compliance professional licensed in the relevant jurisdiction. Tax outcomes in particular depend on facts, structure, accounting method, and state law that are specific to each business.
No reliance; sources. Information here is drawn from sources believed reliable as of June 2026, including government orders and notices and published legal and industry analyses, but no representation or warranty is made as to its accuracy, completeness, or currency. The author owes no duty of update. Any reliance you place on this article is at your own risk.
Limitation of liability. To the fullest extent permitted by law, the author disclaims all liability for any loss or damage arising from any use of, or reliance on, this article. This article is provided for personal, non-commercial reading only; its receipt does not create a client, fiduciary, or advisory relationship of any kind.
Conflicts and compensation. As of the date of publication, the author holds no position, long or short, in any security mentioned or referenced in this article, and has no advisory, consulting, or business relationship with, and receives no compensation from, any cannabis company. This article is published as general professional commentary and is not the product of any engagement.
About the author. Gregg Carlson is a fractional CFO and Controller and a CPA (license inactive, Nevada). References to prior engagements, including financings and SEC reporting for cannabis operators, are provided as background on relevant experience and are not a guarantee or prediction of any result. This article is not an audit, attestation, or assurance engagement, and no such engagement is created by reading it. Past results do not guarantee future outcomes.
